Promising combo tackles rare lymphoma in Real-World trial
NCT ID NCT07233720
First seen Nov 18, 2025 · Last updated May 21, 2026 · Updated 22 times
Summary
This study is testing a combination of two drugs, zanubrutinib and rituximab, as a first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 adults will take part to see how well the combo shrinks tumors and keeps the disease from progressing. The goal is to control the cancer, not cure it, and researchers will also track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.